Ariel Weinberger | Chief Executive Officer
Autonomous Therapeutics

Dr. Ariel Weinberger is the CEO & Founder of Autonomous Therapeutics. Ari started Autonomous from a single bench in the Brooklyn Navy Yard in 2017, and grew the company to a team of more than 20 at Johnson & Johnson’s JLABS incubator in New York City. At JLABS, Autonomous was selected as one of the first companies for J&J’s Blue Knight collaboration with BARDA. Ari and the team have raised substantial funding from the U.S. Government and venture capital—and have developed a new class of RNA (Encrypted RNA™) that enables precision and resistance-proof therapeutics from COVID-19 to Hepatitis B. Ari completed his Ph.D. in Biophysics at the University of California, Berkeley, where he was a DoD NDSEG fellow and received the California HIV/AIDS Dissertation Prize. He completed his postdoctoral training as an NIH Ruth L. Kirschstein Fellow at Harvard. Prior to founding Autonomous, Ari was a Principal Investigator and Wyss Institute Technology Development Fellow at Harvard Medical School.